Insulin absorption: a major factor in apparent insulin resistance and the control of type 2 diabetes mellitus

Metabolism: Clinical and Experimental
Samuel J FriedbergRobert I Gregerman

Abstract

Our experience over many years from 2 diabetes clinics with large patient populations indicated that, apparently, excessive doses of intermediate-acting insulin preparations (150-300 U of NPH insulin), alone or in combination with rapid-acting insulin, generally did not result in acceptable control of fasting blood glucose. We hypothesized that insulin resistance at the tissue level and the known variability of insulin absorption were not satisfactory explanations. To deal with the ambiguities of available data on insulin absorption, we elected to measure insulin bioavailability via a different approach. Thirteen publications provided plasma insulin concentrations after the subcutaneous administration of defined doses of insulin. These data were then analyzed by noncompartmental analysis and by standard pharmacokinetic methods. Analyses required only knowledge of the areas under the plasma insulin curve and the metabolic clearance rate of insulin. Both of these are parameters measurable with considerable accuracy. Quantitative pharmacokinetic analysis of published insulin absorption curves for insulin administered subcutaneously revealed mean absorption levels for regular and lispro insulin of 70 to 80%, 30% or less for NPH ins...Continue Reading

References

Nov 16, 1978·European Journal of Clinical Pharmacology·K KølendorfT Deckert
Nov 1, 1975·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·D L HorwitzN Yanaihara
Mar 1, 1992·Diabetes Care·R A DeFronzoE Ferrannini
Feb 1, 1988·The Journal of Clinical Investigation·K S PolonskyE Van Cauter
Feb 1, 1988·The Journal of Clinical Investigation·K S PolonskyE Van Cauter
Jul 17, 1986·The New England Journal of Medicine·D S Schade, W C Duckworth
May 1, 1974·The Journal of Clinical Investigation·R S SherwinR Andres
Mar 1, 1984·Diabetes Care·C BinderS Pramming
Feb 9, 1984·The New England Journal of Medicine·D M NathanJ D Goodson
Jul 17, 1982·British Medical Journal·T LauritzenC Binder
Sep 1, 1980·The Journal of Clinical Endocrinology and Metabolism·R P EatonJ Standefer
Aug 13, 1981·The New England Journal of Medicine·G R FreidenbergJ V Santiago
Sep 1, 1981·Acta Endocrinologica·R A DeFronzoO K Faber
May 20, 1982·The New England Journal of Medicine·D ElahiR Andres
Mar 1, 1993·Metabolism: Clinical and Experimental·A N PeirisA Nakagawa
Nov 27, 2002·Diabetes Technology & Therapeutics·Lutz Heinemann
Oct 1, 1960·The Journal of Clinical Investigation·S J FRIEDBERGE H ESTES
Oct 1, 1961·The Journal of Clinical Investigation·S J FRIEDBERGE H ESTES
Jan 5, 2005·Diabetes Technology & Therapeutics·Lutz Heinemann, James H Anderson
Apr 27, 2005·The American Journal of Medicine·Irl B Hirsch
Sep 21, 2006·Infectious Disease Clinics of North America·David Andes

❮ Previous
Next ❯

Citations

Jan 24, 2009·The Annals of Thoracic Surgery·Harold L LazarUNKNOWN Society of Thoracic Surgeons Blood Glucose Guideline Task Force
Dec 5, 2012·ISRN Cardiology·Harold L Lazar
Jun 13, 2013·Computer Methods and Programs in Biomedicine·Zimei WuStephen Chang
Aug 17, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Amnon C SintovShafir Botner
Jan 30, 2010·Best Practice & Research. Clinical Anaesthesiology·Anthony P Furnary
Jun 28, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Tue SøeborgMorten Colding-Jørgensen
Jul 10, 2008·The Journal of Clinical Endocrinology and Metabolism·Thomas LinnReinhard G Bretzel
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.